Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    REVIEW

    Progress on Platinum-Based Catalyst Layer Materials for H-PEMFC

    Stefanos Tzelepis*, Kosmas A. Kavadias

    Energy Engineering, Vol.119, No.5, pp. 1745-1769, 2022, DOI:10.32604/ee.2022.020984 - 21 July 2022

    Abstract

    The constant increase in energy demand and related environmental issues have made fuel cells an attractive technology as an alternative to conventional energy technologies. Like any technology, fuel cells face drawbacks that scientific society has been focused on to improve and optimize the overall technology. Thus, the cost is the main inhibitor for this technology due to the significantly high cost of the materials used in catalyst layers. The current discussion mainly focuses on the fundamental electrochemical half-cell reaction of hydrogen oxidation reaction (HOR) and oxygen reduction reaction (ORR) that are taking place in the

    More >

  • Open Access

    ARTICLE

    Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy

    Yue-shen Wang*1, Jing Tian†1, Yong Han, Shu-mei Han, Sheng-bin Shi

    Oncology Research, Vol.24, No.2, pp. 129-135, 2016, DOI:10.3727/096504016X14618564639213

    Abstract We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line treatment after platinum-based chemotherapy failure between May 2009 and April 2012. Dosage: gemcitabine 1,000 mg/m2 plus vinorelbine 25 mg/m2 ; all drugs were administered on days 1 and 8 of a 21-day cycle, and this was continued until failure or unacceptable toxicity. A total of 125 cycles of treatment were administered, and all patients received at least two cycles of treatment (two to five cycles;… More >

Displaying 1-10 on page 1 of 2. Per Page